Metformin Protects against Experimental Acrylamide Neuropathy in Rats. Issue 7 (3rd August 2017)

• Record Type: Journal Article
• Authors: Oda, Samah S.
• Is Part Of: Drug development research. Volume 78:Issue 7(2017)
• Page Start: 349
• Page End: 359
• Publication Date: 2017-08-03
• Subjects: metformin -- acrylamide -- neuropathy -- apoptosis; Drug development -- Periodicals; Drugs -- Research -- Periodicals; 615.19
• DOI: 10.1002/ddr.21400
• Languages: English
• ISSNs: 0272-4391

Abstract

ABSTRACT: Preclinical Research To investigate the potential neuroprotective effects of metformin against experimental acrylamide neuropathy in rats, 24 rats were distributed into four equal groups (6 each). Group 1 was kept as a control. Group 2 (MET) was orally given metformin (200 mg/kg BW/day). Group 3 (ACR) was injected IP with acrylamide (50 mg/kg BW/day). Animals in group 4 (ACR + MET) were administered both MET and ACR at the same dose and route used in groups 2 and 3. Treatments were administered three times a week for three weeks. ACR induced an increase in lipid peroxidation in brain and spinal cord. This was associated with down regulation of bcl2 and up regulation of caspase3 in cerebrum, cerebellum, spinal cord, and sciatic nerve in the ACR‐treated group. ACR‐treated rats revealed neuronal degeneration and glial cell reaction in brain and spinal cord with axonal degeneration and myelin sheath irregularities in sciatic nerve. MET restored lipid peroxidation in brain and spinal cord, decreased caspase3 activity and up regulated bcl2 expression in cerebrum and sciatic nerve. Histopathological findings in ACR + MET group were lesser severe than those established in ACR‐group indicating that MET ameliorates the neuropathic effects of ACR in rats. Drug Dev Res 78 : 349‐359, 2017. © 2017 Wiley Periodicals, Inc.